Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07056699 · ClinicalTrials.gov registry record · Phase 3
SGLT2i, Pioglitazone, and Ketone Production in T1D
A Phase 3 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Not yet
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT07056699: Clinical Trial Phase 3 study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT07056699 is a Phase 3 study that has not yet begun recruiting, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 24 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07056699, a Phase 3 study, has not yet begun recruiting, sponsored by The University of Texas Health Science Center at San Antonio.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future. In patients with Type 1 Diabetes (T1D), Dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i) is known to increase production of glucose in the liver, increase breakdown of fats (lipolysis), and increase production of ketones (ketogenesis). Ketones are chemicals produced by the liver when the body breaks down fat for energy instead of glucose. When the level of ketones in the body becomes too high, a condition called ketoacidosis develops. In this study, the study team will investigate whether adding pioglitazone (a medication commonly used to treat type 2 diabetes), can reduce the Dapagliflozin - induced liver glucose production, fat break down (lipolysis) and ketone body production (ketogenesis) in patients with Type 1 Diabetes (T1D).
Primary Outcome
Infusions of a tracer, ³H-glucose, will begin and continue until the end of the study. A single dose of empagliflozin (25 mg) by mouth will be taken at 900am. Blood samples will be collected minutes to assess how your body responds to the infused tracers. This tracer help to measure the rate of endogenous (liver) glucose production. The difference in levels of EGP will be reported from the beginning of the study to a second level taken 16 weeks later.
Interventions
- OTHER Placebo
- DRUG Dapagliflozin 10mg Tab
- DRUG Pioglitazone 15 MG and 30mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
What is known before NCT07056699 opens enrollment
NCT07056699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07056699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07056699 about?
NCT07056699 is a clinical study titled "SGLT2i, Pioglitazone, and Ketone Production in T1D". Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future. In patients with Type 1 Diabetes (T1D), Dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i)...
What is the current status of trial NCT07056699?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2026-07-01. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT07056699?
The interventions under investigation include: Placebo (OTHER), Dapagliflozin 10mg Tab (DRUG), Pioglitazone 15 MG and 30mg (DRUG).
Who is sponsoring clinical trial NCT07056699?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07056699's enrollment target sits among peer trials
24 1943rd of 2000 higher than 49 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI